Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
99.79
+1.39 (1.41%)
At close: Mar 9, 2026, 4:00 PM EDT
98.00
-1.79 (-1.79%)
After-hours: Mar 9, 2026, 6:59 PM EDT
Revolution Medicines Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 383.75 | 543.06 | 696.15 | 161.41 | 108.5 | Upgrade
|
| Short-Term Investments | 1,642 | 1,746 | 1,157 | 483.53 | 468.56 | Upgrade
|
| Cash & Short-Term Investments | 2,026 | 2,289 | 1,853 | 644.94 | 577.05 | Upgrade
|
| Cash Growth | -11.52% | 23.55% | 187.31% | 11.77% | 30.93% | Upgrade
|
| Receivables | - | - | 1.25 | 4.67 | 5.93 | Upgrade
|
| Prepaid Expenses | 49.36 | 38.33 | 25.07 | 10.57 | 6.79 | Upgrade
|
| Total Current Assets | 2,075 | 2,328 | 1,879 | 660.19 | 589.77 | Upgrade
|
| Property, Plant & Equipment | 165.28 | 141.82 | 100.01 | 73.74 | 71.24 | Upgrade
|
| Goodwill | 14.61 | 14.61 | 14.61 | 14.61 | 14.61 | Upgrade
|
| Other Intangible Assets | 55.8 | 56.67 | 57.74 | 58.81 | 59.88 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.5 | Upgrade
|
| Other Long-Term Assets | 43.79 | 17.57 | 10.06 | 4.59 | 2 | Upgrade
|
| Total Assets | 2,355 | 2,558 | 2,062 | 811.93 | 737.99 | Upgrade
|
| Accounts Payable | 64.62 | 54.43 | 61.79 | 21.31 | 14.06 | Upgrade
|
| Accrued Expenses | 201.48 | 96.03 | 70.8 | 28.94 | 27.41 | Upgrade
|
| Current Portion of Leases | 16.47 | 12.87 | 7.37 | 6.77 | 6.21 | Upgrade
|
| Current Unearned Revenue | - | - | - | 4.46 | 12.36 | Upgrade
|
| Other Current Liabilities | 7.86 | 0.58 | 3.9 | 0.51 | 0.31 | Upgrade
|
| Total Current Liabilities | 290.42 | 163.91 | 143.85 | 61.98 | 60.35 | Upgrade
|
| Long-Term Debt | 268.45 | - | - | - | - | Upgrade
|
| Long-Term Leases | 142.23 | 122.97 | 80.58 | 57.43 | 60.42 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 6.57 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 2.35 | 2.35 | 3.12 | 7.03 | 7.44 | Upgrade
|
| Other Long-Term Liabilities | 19.75 | 3.86 | 7.97 | 0.3 | 0.63 | Upgrade
|
| Total Liabilities | 723.21 | 293.1 | 235.51 | 126.74 | 135.42 | Upgrade
|
| Common Stock | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 4,497 | 4,002 | 2,963 | 1,388 | 1,056 | Upgrade
|
| Retained Earnings | -2,869 | -1,738 | -1,138 | -701.34 | -452.64 | Upgrade
|
| Comprehensive Income & Other | 3.24 | 1.32 | 0.54 | -1.78 | -0.38 | Upgrade
|
| Total Common Equity | 1,631 | 2,265 | 1,826 | 685.19 | 602.57 | Upgrade
|
| Shareholders' Equity | 1,631 | 2,265 | 1,826 | 685.19 | 602.57 | Upgrade
|
| Total Liabilities & Equity | 2,355 | 2,558 | 2,062 | 811.93 | 737.99 | Upgrade
|
| Total Debt | 427.15 | 135.84 | 87.94 | 64.21 | 66.63 | Upgrade
|
| Net Cash (Debt) | 1,599 | 2,153 | 1,765 | 580.74 | 510.42 | Upgrade
|
| Net Cash Growth | -25.77% | 22.01% | 203.93% | 13.78% | 25.08% | Upgrade
|
| Net Cash Per Share | 8.41 | 12.84 | 15.60 | 7.20 | 7.01 | Upgrade
|
| Filing Date Shares Outstanding | 198.17 | 185.91 | 164.69 | 90.49 | 74.19 | Upgrade
|
| Total Common Shares Outstanding | 197 | 185.9 | 164.67 | 90.41 | 74.14 | Upgrade
|
| Working Capital | 1,785 | 2,164 | 1,735 | 598.2 | 529.42 | Upgrade
|
| Book Value Per Share | 8.28 | 12.19 | 11.09 | 7.58 | 8.13 | Upgrade
|
| Tangible Book Value | 1,561 | 2,194 | 1,754 | 611.77 | 528.08 | Upgrade
|
| Tangible Book Value Per Share | 7.92 | 11.80 | 10.65 | 6.77 | 7.12 | Upgrade
|
| Machinery | 39.38 | 31.44 | 28.09 | 21.74 | 14.98 | Upgrade
|
| Construction In Progress | 0.05 | 0.39 | 0.51 | - | 0.13 | Upgrade
|
| Leasehold Improvements | 22.28 | 14.28 | 11.95 | 11.4 | 7.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.